Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 14/20 | 1.00 |
| ▸ | IL1B | P01584 | 6/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCNK | O75909 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL25209299 | 0.96 | NLRP3 (1.00) | NLRP3IL1BKCNH2 | |
| SCHEMBL30833871 | 0.91 | NLRP3 (0.83) | NLRP3IL1BKCNH2 | |
| SCHEMBL25194198 | 0.90 | NLRP3 (1.00) | NLRP3IL1BKCNH2CCNT1CCNK | |
| SCHEMBL25519373 | 0.88 | NLRP3 (0.79) | NLRP3IL1BKCNH2CCNT1CCNK | |
| SCHEMBL31042127 | 0.88 | NLRP3 (0.79) | NLRP3IL1BKCNH2CCNT1CCNK | |
| SCHEMBL26773537 | 0.88 | NLRP3 (0.78) | NLRP3IL1B | |
| SCHEMBL25214158 | 0.88 | NLRP3 (0.78) | NLRP3IL1BKCNH2CCNT1CCNK | |
| SCHEMBL26772226 | 0.86 | NLRP3 (0.75) | NLRP3IL1BKCNH2 | |
| SCHEMBL26772223 | 0.85 | NLRP3 (0.75) | NLRP3IL1BKCNH2 | |
| SCHEMBL25255374 | 0.85 | NLRP3 (0.73) | NLRP3IL1BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4433459-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | F. Hoffmann-La Roche AG (CH) | 2024-09-25 | — | — | EP | claimed |
| US-20240308977-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | HOFFMANN-LA ROCHE INC. (US) | 2024-09-19 | — | — | US | claimed |
| CN-118265701-A | Pyridazine derivatives as inhibitors of NLRP3 | 豪夫迈·罗氏有限公司 | 2024-06-28 | — | — | CN | claimed |
| WO-2023088987-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | claimed |
| EP-4433459-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | F. Hoffmann-La Roche AG (CH) | 2024-09-25 | — | — | EP | disclosed |
| US-20240308977-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | HOFFMANN-LA ROCHE INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-118265701-A | Pyridazine derivatives as inhibitors of NLRP3 | 豪夫迈·罗氏有限公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2023088987-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023088987-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308977-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | NLRP3, NLRP1, PYCARD | NLRP3 1/4885IL1B 8/4885KCNH2 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.